Mei Liu
- Molecular Biology top 10%
- Oncology top 5%
- Epidemiology top 10%
- Cancer Research top 10%
- Immunology top 10%
- Topics
- Rheumatoid Arthritis Research and Therapies (13 papers)Natural product bioactivities and synthesis (13 papers)Bone Metabolism and Diseases (9 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Mei Liu
123 papers receiving 3.1k citations
Peers
Comparison fields: 5 of 149
- Molecular Biology 1.2k
- Oncology 503
- Epidemiology 447
- Cancer Research 286
- Immunology 273
Countries citing papers authored by Mei Liu
This map shows the geographic impact of Mei Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei Liu more than expected).
Fields of papers citing papers by Mei Liu
This network shows the impact of papers produced by Mei Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei Liu. The network helps show where Mei Liu may publish in the future.
Co-authorship network of co-authors of Mei Liu
This figure shows the co-authorship network connecting the top 25 collaborators of Mei Liu. A scholar is included among the top collaborators of Mei Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei Liu. Mei Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 5 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 5 | |
| 8 | ALP Inhibitors Inhibit Inflammatory Responses and Osteoblast Differentiation in hVIC via AKT-ERK Pathways. | 2 |
| 9 | 5 | |
| 10 | 8 | |
| 11 | 12 | |
| 12 | 0 | |
| 13 | 36 | |
| 14 | 0 | |
| 15 | 18 | |
| 16 | 14 | |
| 17 | 32 | |
| 18 | 14 | |
| 19 | 4 | |
| 20 | 32 |
About Mei Liu
Mei Liu is a scholar working on Cancer Research, Hepatology and Oncology, having authored 129 papers that have together received 3.1k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (13 papers), Natural product bioactivities and synthesis (13 papers) and Bone Metabolism and Diseases (9 papers). The work is most often cited by research in Physiology (143 citations), Pharmacology (226 citations) and Complementary and alternative medicine (210 citations). Mei Liu has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Yubin Luo, Yufeng Xia, Li Yu, Zhunan Gong, Jiake Xu, Yun‐Qiong Gu, Yan‐Cheng Liu, Ke-Bin Huang, Zhen‐Feng Chen and Hong Liang. Their work appears in journals such as ACS Nano, Gastroenterology and Nature Cell Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.